T. Jensen

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial

I. Hirsch, T. Pieber, C. Mathieu, 2016, Diabetes Care.

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial

A. Astrup, L. Breum, T. Larsen, 2008, The Lancet.

[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].

A. Astrup, L. Breum, T. Larsen, 2009, Ugeskrift for laeger.

Under-reporting of adverse effects of tesofensine

A. Astrup, L. Breum, T. Larsen, 2013, The Lancet.

Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial

J. Buse, M. Nauck, S. Calanna, 2018, Diabetes Care.

Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial

Matthew J. Crowley, S. Verma, D. McGuire, 2020, Diabetes Care.